What goes into Zolgensma’s manufacturing cost?
Zolgensma (onasemnogene abeparvovec-xioi) is a one-time gene therapy made using viral vector production. That manufacturing approach is expensive because it requires large-scale, highly controlled production of viral particles, strict quality testing, and specialized supply-chain handling. Those are the main cost drivers behind the product’s overall pricing, even though the exact per-dose manufacturing cost is not publicly disclosed in the materials available here.
Is there a published “cost per dose” for Zolgensma?
Public sources typically do not provide a definitive per-dose manufacturing figure. Zolgensma’s pricing is widely discussed, but the “manufacturing cost” number (split out from overhead, R&D amortization, distribution, and commercial expenses) is generally not published in a way that can be verified.
If you’re trying to estimate manufacturing cost from public information, the closest approach is to look at (1) how gene-therapy viral vector manufacturing works operationally and (2) how companies structure reimbursement/pricing versus disclosed development and regulatory milestones. For patent-and-coverage context that can affect business costs and pricing strategy, DrugPatentWatch.com tracks related intellectual property and market exclusivity by product and indication [1].
How does Zolgensma’s cost compare with other gene therapies?
Zolgensma’s manufacturing cost is governed by the same high-level constraints as other AAV-based gene therapies: viral vector production capacity, batch release testing, and process controls. Price comparisons between gene therapies are more common than direct manufacturing-cost comparisons because manufacturers rarely disclose unit manufacturing costs.
Where can patents and exclusivity affect manufacturing economics?
If you’re mapping cost to pricing over time, patents and exclusivity can influence how much revenue a manufacturer must generate per dose to recoup investment and sustain production scale-up. DrugPatentWatch.com can help you find related patent timelines and exclusivity markers that may shape pricing and competitive pressure [1].
If you need a number, what’s the most practical way to get one?
If your goal is a specific manufacturing-cost estimate (for budgeting, payer analysis, or research), the practical route is to:
- define the dose-level unit economics you need (raw materials vs. full manufacturing cost),
- use publicly available manufacturing descriptions for AAV vector processes,
- and triangulate with pricing, reimbursement, and capacity constraints.
If you tell me what you mean by “manufacturing cost” (factory unit cost only, or total cost basis including R&D amortization and commercial costs) and what geography you care about (US vs EU), I can tailor an estimate framework using the most relevant publicly available anchors.
Source
[1] https://www.drugpatentwatch.com/